Technology
Health
Biotechnology

Coherus BioSciences

$20.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CHRS and other stocks, options, ETFs, and crypto commission-free!

About

Coherus BioSciences, Inc. Common Stock, also called Coherus BioSciences, is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Read More Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Employees
232
Headquarters
Redwood City, California
Founded
2010
Market Cap
1.41B
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
744.11K
High Today
$20.60
Low Today
$19.80
Open Price
$20.58
Volume
451.55K
52 Week High
$21.18
52 Week Low
$8.32

Collections

Technology
Health
Biotechnology
Medical
Therapy
2014 IPO
US
North America

News

Seeking AlphaMay 9

Coherus BioSciences, Inc. CEO Denny Lanfear on Q1 2019 Results - Earnings Call Transcript

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants David Arrington - VP, IR and Corporate Affairs Denny Lanfear - President, Chief Executive Officer and Chairman Jean Viret - Chief Financial Officer Jim Hassard - SVP, Marketing and Market Access Conference Call Participants Ken Cacciatore - Cowen and Company Chris Schott - JPMorgan Mohit Bansal - Citi Douglas Tsao - H.C. Wainwright Operator Ladies and gentlemen, thank you for stan...

63
Yahoo FinanceMay 9

Coherus BioSciences Reports Q1 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 36.96% and 0.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

30
Yahoo FinanceMay 8

Did Hedge Funds Drop The Ball On Coherus Biosciences Inc (CHRS) ?

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors.

44

Earnings

-$1.09
-$0.73
-$0.36
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
β€”
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.